IPT for Major Depression Following Perinatal Loss: Healing After Loss (HeAL)

Sponsor
Michigan State University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04629599
Collaborator
Women and Infants Hospital of Rhode Island (Other)
274
1
2
48
5.7

Study Details

Study Description

Brief Summary

This study tests the efficacy of interpersonal psychotherapy (IPT) for major depression following perinatal loss (early and late fetal death and early neonatal death) in a sample of 274 women in Flint and Detroit, Michigan. The trial will be the first fully powered randomized trial of treatment for any psychiatric disorder following perinatal loss.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Interpersonal psychotherapy for major depression following perinatal loss
  • Behavioral: Coping with Depression
Phase 2/Phase 3

Detailed Description

The goal of this study is to conduct a fully-powered randomized efficacy study of IPT for MDD following perinatal loss. Our perinatal-loss adapted group IPT will be compared to a standard depression intervention (CWD, also delivered in a group format) in a sample of 274 women experiencing MDD following perinatal loss. The proposed randomized controlled trial (RCT) will test the hypotheses that: (1) IPT for perinatal loss will result in reduced time to recovery from MDD (primary), depressive symptoms, and PTSD symptoms (secondary) relative to CWD; and that among women meeting criteria for PTSD, IPT will result in reduced time to recovery from PTSD; (2) IPT for perinatal loss will result in increased social support, social role functioning (including parental functioning for women with living children), and well-being, and decreased grief and fear of subsequent pregnancies, relative to CWD; and (3) social support and grief will mediate the effects of IPT on time to MDD recovery.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
274 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
IPT for Major Depression Following Perinatal Loss: Healing After Loss (HeAL)
Actual Study Start Date :
Sep 1, 2021
Anticipated Primary Completion Date :
Jan 15, 2025
Anticipated Study Completion Date :
Aug 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Interpersonal psychotherapy for major depression following perinatal loss

Participants in the IPT condition will receive 12 group sessions and 2 individual (pre-group and 1-month booster) sessions as outlined in the manual The individual sessions prepare patients to use the group effectively, to keep group members focused on their treatment goals, and to maintain treatment gains. In addition, 3 of the 12 group sessions will invite women to include their partners or other support people to bolster the woman's social support system and to reduce conflicts over how to react to the loss. These sessions are important because relationship distress is common following perinatal loss. Our IPT intervention allows new women to enter the group every 4 weeks of the 12-week group. Group sessions are semi-structured, and each woman will cover the four group topics three times, approaching each topic from a different stage in the mourning process.

Behavioral: Interpersonal psychotherapy for major depression following perinatal loss
Participants in the IPT condition will receive 12 group sessions and 2 individual (pre-group and 1-month booster) sessions as outlined in the manual The individual sessions prepare patients to use the group effectively, to keep group members focused on their treatment goals, and to maintain treatment gains. In addition, 3 of the 12 group sessions will invite women to include their partners or other support people to bolster the woman's social support system and to reduce conflicts over how to react to the loss. These sessions are important because relationship distress is common following perinatal loss. Our IPT intervention allows new women to enter the group every 4 weeks of the 12-week group. Group sessions are semi-structured, and each woman will cover the four group topics three times, approaching each topic from a different stage in the mourning process.
Other Names:
  • IPT
  • Active Comparator: Coping with Depression

    The Coping with Depression (CWD) course is a structured, manualized psycho-educational group treatment for MDD. The CWD course is based on social learning theory which posits that depression is associated with a decrease in pleasant and an increase in unpleasant person-environment interactions. The problems shown by depressed individuals are viewed as behavioral, with cognitive patterns that can be unlearned or relearned. Its effectiveness is comparable to other forms of psychotherapy in depression. The course content is cognitive-behavioral in nature and is designed to train skills that can be used in the alleviation of depression. The skill modules focus on relaxation, cognitive skills, and behavioral activation. As in the pilot trial, CWD will consist of an individual pregroup session, 12 group therapy sessions (allowing new women to enter every 4th session) and a 1-month individual booster session to provide an identical treatment dose as the experimental condition.

    Behavioral: Coping with Depression
    The Coping with Depression (CWD) course is a structured, manualized psycho-educational group treatment for MDD. The CWD course is based on social learning theory which posits that depression is associated with a decrease in pleasant and an increase in unpleasant person-environment interactions. The problems shown by depressed individuals are viewed as behavioral, with cognitive patterns that can be unlearned or relearned. Its effectiveness is comparable to other forms of psychotherapy in depression. The course content is cognitive-behavioral in nature and is designed to train skills that can be used in the alleviation of depression. The skill modules focus on relaxation, cognitive skills, and behavioral activation. As in the pilot trial, CWD will consist of an individual pregroup session, 12 group therapy sessions (allowing new women to enter every 4th session) and a 1-month individual booster session to provide an identical treatment dose as the experimental condition.
    Other Names:
  • CWD
  • Outcome Measures

    Primary Outcome Measures

    1. Time to Major Depressive Disorder recovery [censored at 28 weeks, the proposed study duration]

      Assessed via the Longitudinal Interview Follow-up Evaluation (LIFE; lower is better)

    Secondary Outcome Measures

    1. Depressive symptoms [8, 16, and 28 weeks after intake]

      Overall score on the Quick Inventory of Depressive Symptoms (QIDS; lower is better)

    2. PTSD symptoms [8, 16, and 28 weeks after intake]

      Life Events Checklist and PTSD Checklist for DSM-5 (LEC-PCL; lower is better)

    3. Time to PTSD recovery [censored at 28 weeks, the proposed study duration]

      Assessed via the Longitudinal Interval Follow-Up Evaluation (LIFE; lower is better)

    4. Overall perceived social support [8, 16, and 28 weeks after intake]

      Overall score of the Multidimensional Scale of Perceived Social Support (higher is better)

    5. Dyadic social support (from partner or another important person) [8, 16, and 28 weeks after intake]

      Overall score of the Relationship Assessment Scale (higher is better)

    6. Social role functioning (including parental functioning) [8, 16, and 28 weeks after intake]

      Overall score of the Short version of the Social Adjustment Scale (SAS) - Self Report and parental functioning SAS subscale (lower is better)

    7. Well-being [8, 16, and 28 weeks after intake]

      Overall score of the NIH Neuro-Quality of Life scale for positive affect and well-being (higher is better)

    8. Grief symptoms [8, 16, and 28 weeks after intake]

      Overall score of the Perinatal Bereavement Grief Scale (lower is better)

    9. Complicated grief symptoms [8, 16, and 28 weeks after intake]

      Overall score of the Inventory of Complicated Grief (lower is better)

    10. Perceived deservingness of loss and guilt over loss [8, 16, an 28 weeks after intake]

      Loss Beliefs Scale (lower is better)

    11. Fear of subsequent pregnancies [8, 16, and 28 weeks after intake]

      Overall score of the Fear of subsequent pregnancies measure (lower is better)

    Other Outcome Measures

    1. Treatment acceptability [16 weeks after intake]

      Client Satisfaction Questionnaire - Revised (CSQ-8-R; higher is better)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 50 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • women who meet current Diagnostic and Statistical Manual 5 (DSM-5) criteria for major depressive disorder (MDD)

    • have experienced a perinatal loss (including early and late fetal death, death of a liveborn neonate within the first 28 days, and medically recommended termination) within the last 1-12 months

    • are 18 to 50 years old

    • speak and understand English well enough to understand questionnaires when they are read aloud

    • can provide the name and contact information of at least two locator persons

    • have access to a telephone through owning one, a relative/friend, or an agency

    Exclusion Criteria:
    • onset of current major depressive episode prior to news of difficulties with the pregnancy or health risk to the infant (women with prior episodes will be included)

    • current or past diagnosis of bipolar disorder, schizophrenia or other psychotic disorder

    • primary diagnosis of current substance use disorder

    • acute suicidal or homicidal risk

    • non-stable course of antidepressant medication or psychotherapy (i.e., beginning or changing dose of either within the previous 12 weeks)

    • any IPT or cognitive-behavioral treatment in the previous 12 weeks

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Anywhere in the entire state of Michigan (treatment is virtual) Flint Michigan United States 48502

    Sponsors and Collaborators

    • Michigan State University
    • Women and Infants Hospital of Rhode Island

    Investigators

    • Principal Investigator: Jennifer E Johnson, PhD, Michigan State University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Jennifer E. Johnson, C. S. Mott Endowed Professor of Public Health, Michigan State University
    ClinicalTrials.gov Identifier:
    NCT04629599
    Other Study ID Numbers:
    • R01HD100471
    First Posted:
    Nov 16, 2020
    Last Update Posted:
    Jun 14, 2022
    Last Verified:
    Jun 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Jennifer E. Johnson, C. S. Mott Endowed Professor of Public Health, Michigan State University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 14, 2022